Lenangio 10 Capsule contains Lenalidomide 10 mg, an immunomodulatory agent indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Lenalidomide exerts antineoplastic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells. It is primarily prescribed as part of combination therapy or as monotherapy in patients with relapsed or refractory disease. The capsule formulation allows for oral administration, facilitating patient compliance. Lenangio 10 Capsule should be used under strict medical supervision due to its potential for serious adverse effects, including hematologic toxicities such as neutropenia and thrombocytopenia, as well as risk of thromboembolism. Regular monitoring of complete blood counts and renal function is essential during treatment. Patients should be advised regarding potential teratogenicity; effective contraception is mandatory for both male and female patients of reproductive potential. Dose adjustments may be necessary in cases of renal impairment or hematologic toxicity. Lenangio 10 Capsule is contraindicated in pregnancy and hypersensitivity to lenalidomide or any excipients. This medication should be dispensed with a comprehensive risk management program to ensure safe use. Always consult a healthcare professional before initiating therapy with Lenangio 10 Capsule.